Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.

Cefalo, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., Giaccari, A., Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives 11 Medical and Health Sciences 1103 Clinical Sciences, <<CARDIOVASCULAR DIABETOLOGY>>, 2019; 18 (1): 20-N/A. [doi:10.1186/s12933-019-0828-y] [http://hdl.handle.net/10807/132547]

Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives 11 Medical and Health Sciences 1103 Clinical Sciences

Cefalo, Chiara Maria Assunta
Primo
;
Cinti, Francesca;Moffa, Simona;Impronta, Flavia;Mezza, Teresa;Pontecorvi, Alfredo;Giaccari, Andrea
Ultimo
2019

Abstract

Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.
2019
Inglese
Cefalo, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., Giaccari, A., Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives 11 Medical and Health Sciences 1103 Clinical Sciences, <<CARDIOVASCULAR DIABETOLOGY>>, 2019; 18 (1): 20-N/A. [doi:10.1186/s12933-019-0828-y] [http://hdl.handle.net/10807/132547]
File in questo prodotto:
File Dimensione Formato  
12933_2019_Article_828.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.54 MB
Formato Adobe PDF
1.54 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/132547
Citazioni
  • ???jsp.display-item.citation.pmc??? 42
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 68
social impact